AVXL
Anavex Life Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVXL
Anavex Life Sciences Corp.
A clinical stage biopharmaceutical company that develops novel drugs to treat Alzheimer's, central nervous system diseases and various types of cancer
630 5th Avenue
20th Floor
New York
NY USA 10111
--
Anavex Life Sciences Corp., founded on January 23, 2004, is located in Nevada. Is a clinical-stage biopharmaceutical company dedicated to the development of differentiated therapies that apply precision medicine to central nervous system (CNS) diseases with high unmet needs. The company's focus is on developing innovative therapies for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative diseases, rare diseases including Rett syndrome, and other central nervous system (CNS) diseases.
Earnings Call
Q3/2025
Estimate EPS-0.14
Actual EPS-0.16
Estimate Revenue--
Actual Revenue0
Anavex Life Sciences' Q3 2025: Navigating Contradictions in EMA Reviews, Commercialization, and Orphan Drug Strategies
Aug 12,2025 10:47
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AVXL has released its 2025 Q4 earnings. EPS was reported at -0.11, versus the expected -0.15, beating expectations. The chart below visualizes how AVXL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
